US puts hold on F-star's takeover by China’s Sino Biopharm, citing national security risks

F-star Therapeutics won’t yet be able to close its deal with its Chinese buyer, after the US government’s Committee on Foreign Investment in the United States panel put a hold on the takeover, citing national security risks.